Description General description A cell-permeable compound that acts as a selective, potent, and reversible inhibitor of non-muscle myosin II. Inhibits the ATPase and gliding motility of human platelets (≤100 µM) without affecting myosin light chain kinase (MLCK) activity. Has been shown to block cell blebbing and to rapidly disrupt directed cell migration and cytokinesis in vertebrate cells. Does not disrupt mitosis or affect contractile ring assembly. Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target ATPase Product does not compete with ATP. Reversible: yes Target IC50: <100 µM inhibiting the ATPase and gliding motility of human platelets Packaging Packaged under inert gas Warning Toxicity: Harmful & Carcinogenic / Teratogenic (E) Physical form A 50 mM (5 mg/342 µl) solution of (±)-Blebbistatin (Cat. No. 203390) in 90% DMSO. Reconstitution Following initial thaw, aliquot and freeze (-20°C). Other Notes Shu, S., et al. 2005. Proc. Natl. Acad. Sci. USA102, 1472. Kovacs, M., et al. 2004. J. Biol. Chem.279, 35557. Straight, A.F., et al. 2003. Science299, 1743. Cheung, A., et al. 2001. Mol. Biol. Cell Suppl.12, 271a.